<DOC>
	<DOCNO>NCT01216644</DOCNO>
	<brief_summary>Patients locally advance resectable adenocarcinoma stomach esophagogastreal junction without previous therapy treat one two chemotherapy combination surgery . One half patient get 5-Fluorouracil ( 5-FU ) , Leucovorin , Oxaliplatin Docetaxel ( FLOT ) , others Epirubicin , Cisplatin 5-FU ( ECF ) . Main objective study median overall survival .</brief_summary>
	<brief_title>5-FU , Leucovorin , Oxaliplatin Docetaxel ( FLOT ) Versus Epirubicin , Cisplatin 5-FU ( ECF ) Patients With Locally Advanced , Resectable Gastric Cancer</brief_title>
	<detailed_description>714 Patients locally advance resectable ( T2-4 and/or N+ , M0 ) adenocarcinoma stomach esophagogastreal junction without previous therapy include study . After randomization patient receive perioperatively 4 cycle FLOT 3 cycle ECF , follow restaging tumour status surgery . Subsequently another 4 cycle FLOT 3 cycle ECF applicated . Then central validation pathological remission rate schedule . Primary endpoint overall survival , secondary endpoint disease free survival , perioperative morbidity mortality , histopathologic regression rate R0-resection rate .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>1. locally advanced ( &gt; T1 ) and/or nodal positive ( N+ ) histologically proven adenocarcinoma esophagogastreal junction ( AEG IIII ) stomach without distant metastasis ( M0 ) without infiltration adjacent structure organs 2. previous surgical resection 3. previous cytostatic chemotherapy 4 . Age &gt; 18 year ( female male ) 5 . ECOG ≤ 2 6. surgical resectability 7 . Exclusion peritoneal carcinomatosis ( clinically suspect ) via laparoscopy 8 . Leucocytes &gt; 3.000/µl 9 . Platelets &gt; 100.000/µl 10 . Serum creatinin ≤ 1.5x normal value , CreatininClearance &gt; 50 ml/min 11. write informed consent . 12 . Ejection fraction &gt; 50 % echocardiography start therapy 1. distant metastasis infiltration adjacent structure organ primarily resectable stage 2. relapse 3 . Hypersensitivity 5 Fluorouracil , Leucovorin , Oxaliplatin , Cisplatin . Epirubicin Docetaxel 4 . Existence contraindication 5 Fluorouracil , Leucovorin , Oxaliplatin , Cisplatin , Epirubicin Docetaxel 5 . Active CHD , Cardiomyopathy cardiac insufficiency stage IIIIV accord NYHA 6. malignant secondary disease , date back &lt; 5 year ( exception : Insitucarcinoma cervix uterus , adequately treat skin basal cell carcinoma ) 7. severe nonsurgical accompany disease acute infection 8. peripheral polyneuropathy &gt; NCI Grad II 9. severe liver dysfunction ( AST/ALT &gt; 3,5xULN , AP &gt; 6xULN , Bilirubin &gt; 1,5xULN ) 10. chronic inflammable gastrointestinal disease 11. inclusion another clinical trial 12. pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>gastric cancer</keyword>
	<keyword>perioperative</keyword>
	<keyword>FLOT</keyword>
	<keyword>ECF</keyword>
	<keyword>pathological complete remission</keyword>
	<keyword>locally advanced resectable adenocarcinoma esophagogastric juction stomach</keyword>
</DOC>